Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis.

Adult Austria / epidemiology Carcinoma, Hepatocellular / epidemiology Disease Progression Female Hepatitis D / diagnosis Humans Liver Cirrhosis / epidemiology Liver Neoplasms / epidemiology Male Middle Aged Prevalence Retrospective Studies
epidemiology hepatitis D viral hepatitis

Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
12 2021
Historique:
received: 13 07 2021
accepted: 19 09 2021
pubmed: 8 12 2021
medline: 24 2 2022
entrez: 7 12 2021
Statut: ppublish

Résumé

Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown. This national study aimed at (i) recording the prevalence of HDV-infection in Austria and (ii) characterizing the "active" HDV cohort in Austria. A total of 10 hepatitis treatment centers in Austria participated in this multicenter study and retrospectively collected their HDV patients between Q1/2010 and Q4/2020. Positive anti-HDV and/or HDV-RNA-polymerase chain reaction (PCR) results were retrieved from local database queries. Disease severity was assessed by individual chart review. Viremic HDV patients with clinical visits in/after Q1/2019 were considered as the "active" HDV cohort. A total of 347 anti-HDV positive patients were identified. In 202 (58.2%) patients, HDV-RNA-PCR test was performed, and 126/202 (62.4%) had confirmed viremia. Hepatocellular carcinoma was diagnosed in 7 (5.6%) patients, 7 (5.6%) patients underwent liver transplantation, and 11 (8.7%) patients died during follow-up. The "active" Austrian HDV cohort included 74 (58.7%) patients: Evidence for advanced chronic liver disease (ACLD, i.e., histological F3/F4 fibrosis, liver stiffness ≥10 kPa, varices, or hepatic venous pressure gradient ≥6 mmHg) was detected in 38 (51.4%) patients, including 2 (5.3%) with decompensation (ascites/hepatic encephalopathy). About 37 (50.0%) patients of the "active" HDV cohort had previously received interferon treatment. Treatment with the sodium-taurocholate cotransporting polypeptide inhibitor bulevirtide was initiated in 20 (27.0%) patients. The number of confirmed HDV viremic cases in Austria is low (<1% of HBV patients) but potentially underestimated. Testing all HBV patients will increase the diagnostic yield. More than half of viremic HDV patients had ACLD. Improved HDV testing and workup strategies will facilitate access to novel antiviral therapies.

Sections du résumé

BACKGROUND
Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown.
OBJECTIVE
This national study aimed at (i) recording the prevalence of HDV-infection in Austria and (ii) characterizing the "active" HDV cohort in Austria.
METHODS
A total of 10 hepatitis treatment centers in Austria participated in this multicenter study and retrospectively collected their HDV patients between Q1/2010 and Q4/2020. Positive anti-HDV and/or HDV-RNA-polymerase chain reaction (PCR) results were retrieved from local database queries. Disease severity was assessed by individual chart review. Viremic HDV patients with clinical visits in/after Q1/2019 were considered as the "active" HDV cohort.
RESULTS
A total of 347 anti-HDV positive patients were identified. In 202 (58.2%) patients, HDV-RNA-PCR test was performed, and 126/202 (62.4%) had confirmed viremia. Hepatocellular carcinoma was diagnosed in 7 (5.6%) patients, 7 (5.6%) patients underwent liver transplantation, and 11 (8.7%) patients died during follow-up. The "active" Austrian HDV cohort included 74 (58.7%) patients: Evidence for advanced chronic liver disease (ACLD, i.e., histological F3/F4 fibrosis, liver stiffness ≥10 kPa, varices, or hepatic venous pressure gradient ≥6 mmHg) was detected in 38 (51.4%) patients, including 2 (5.3%) with decompensation (ascites/hepatic encephalopathy). About 37 (50.0%) patients of the "active" HDV cohort had previously received interferon treatment. Treatment with the sodium-taurocholate cotransporting polypeptide inhibitor bulevirtide was initiated in 20 (27.0%) patients.
CONCLUSION
The number of confirmed HDV viremic cases in Austria is low (<1% of HBV patients) but potentially underestimated. Testing all HBV patients will increase the diagnostic yield. More than half of viremic HDV patients had ACLD. Improved HDV testing and workup strategies will facilitate access to novel antiviral therapies.

Identifiants

DOI: 10.1002/ueg2.12163 PMID: 34873866 PMC: PMC8672089
pubmed: 34873866
doi: 10.1002/ueg2.12163
pmc: PMC8672089
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1119-1127

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.

Références

Antiviral Res. 2021 Jan;185:104995
pubmed: 33321155
J Hepatol. 2021 May;74(5):1200-1211
pubmed: 33484770
Curr Gastroenterol Rep. 2014 Feb;16(2):372
pubmed: 24452634
J Hepatol. 2020 Nov;73(5):1046-1062
pubmed: 32634548
Dig Liver Dis. 2019 Mar;51(3):438-442
pubmed: 30314950
Liver Int. 2021 Feb;41(2):295-299
pubmed: 33217778
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Drugs. 2020 Oct;80(15):1601-1605
pubmed: 32926353
J Hepatol. 2021 Mar;74(3):686-699
pubmed: 33276031
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
United European Gastroenterol J. 2021 Dec;9(10):1119-1127
pubmed: 34873866
Hepatology. 2020 Oct;72(4):1177-1190
pubmed: 32145073
J Clin Virol. 2014 Oct;61(2):286-8
pubmed: 25151628
J Hepatol. 2017 Feb;66(2):297-303
pubmed: 27746337
Lancet Infect Dis. 2019 Mar;19(3):275-286
pubmed: 30833068
Liver Int. 2018 May;38(5):842-850
pubmed: 28963781
N Engl J Med. 2011 Jan 27;364(4):322-31
pubmed: 21268724
Liver Int. 2021 Jul;41(7):1509-1517
pubmed: 33999515
J Gastrointestin Liver Dis. 2015 Dec;24(4):413-21
pubmed: 26697566
Hepatology. 2021 Dec;74(6):3479-3485
pubmed: 34331781
J Clin Microbiol. 2005 May;43(5):2363-9
pubmed: 15872267
Liver Int. 2021 Jun;41 Suppl 1:30-37
pubmed: 34155804
Liver Int. 2019 Nov;39(11):2077-2081
pubmed: 31505080
Infection. 2017 Jun;45(3):277-281
pubmed: 27817147
J Hepatol. 2015 Jul;63(1):237-64
pubmed: 25911335
J Hepatol. 2019 Oct;71(4):834-839
pubmed: 31302176

Auteurs

Mathias Jachs (M)

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
HIV and Liver Disease Study Group, Medical University of Vienna, Vienna, Austria.
ORCID: 0000-0003-2871-4147

Teresa Binter (T)

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
HIV and Liver Disease Study Group, Medical University of Vienna, Vienna, Austria.

Caroline Schmidbauer (C)

HIV and Liver Disease Study Group, Medical University of Vienna, Vienna, Austria.
Division of Gastroenterology and Hepatology, Department of Medicine II, Klinik Ottakring, Vienna, Austria.

Lukas Hartl (L)

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
HIV and Liver Disease Study Group, Medical University of Vienna, Vienna, Austria.

Michael Strasser (M)

First Department of Medicine, Paracelsus Medical University, Salzburg, Austria.

Hermann Laferl (H)

Department of Infectious Diseases and Tropical Medicine, Klinik Favoriten, Vienna, Austria.

Stephanie Hametner-Schreil (S)

Department of Gastroenterology and Hepatology, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria.

Alexander Lindorfer (A)

Department of Gastroenterology and Hepatology, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria.

Kristina Dax (K)

Department of Internal Medicine and Gastroenterology and Hepatology, Kepler Universitätsklinikum, Linz, Austria.

Rudolf E Stauber (RE)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
ORCID: 0000-0002-3687-9331

Harald H Kessler (HH)

Institute for Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria.

Sebastian Bernhofer (S)

Department of Internal Medicine II, University Hospital St. Pölten, St. Pölten, Austria.

Andreas Maieron (A)

Department of Internal Medicine II, University Hospital St. Pölten, St. Pölten, Austria.

Lorin Loacker (L)

Central Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Innsbruck, Innsbruck, Austria.

Simona Bota (S)

Department of Internal Medicine and Gastroenterology, Hepatology, Endocrinology, Rheumatology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.

Isabel Santonja (I)

Center for Virology, Medical University of Vienna, Vienna, Austria.

Petra Munda (P)

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Mattias Mandorfer (M)

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
HIV and Liver Disease Study Group, Medical University of Vienna, Vienna, Austria.
ORCID: 0000-0003-2330-0017

Markus Peck-Radosavljevic (M)

Department of Internal Medicine and Gastroenterology, Hepatology, Endocrinology, Rheumatology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
ORCID: 0000-0002-0597-2728

Heidemarie Holzmann (H)

Center for Virology, Medical University of Vienna, Vienna, Austria.

Michael Gschwantler (M)

HIV and Liver Disease Study Group, Medical University of Vienna, Vienna, Austria.
Division of Gastroenterology and Hepatology, Department of Medicine II, Klinik Ottakring, Vienna, Austria.

Heinz Zoller (H)

Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.

Peter Ferenci (P)

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Thomas Reiberger (T)

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
HIV and Liver Disease Study Group, Medical University of Vienna, Vienna, Austria.
ORCID: 0000-0002-4590-3583

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › Régions géographiques › Europe › Autriche › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Hépatite › Hépatites virales humaines › Hépatite D › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Cirrhose du foie › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Hepatitis D virus (HDV) prevalence in Austria...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Hepatitis D virus (HDV) prevalence in Austria...